Jing Q, Jianyong L, Jiming Y, Shuren L, Rui W, Wei L
Tianjin Hepatopathy Research Institute, Tianjin Second People's Hospital, Tianjin 300192, PR, China.
Indian J Cancer. 2015 Dec;52 Suppl 2:e105-6. doi: 10.4103/0019-509X.172504.
The purpose of this study was to evaluate the predictive value of recurrence for serum hypoxia inducible factor-1α (HIF-1α), C-reaction protein (CRP) in hepatocellular carcinoma patients after transcatheter arterial chemoembolization (TACE).
Fifty-eight hepatocellular carcinoma patients treated with TACE were included in this study from February 2010 to January 2013 as the case group. Of the included 58 cases, 47 patients had recurrence disease, and other 11 cases had no recurrence disease within 2 years follow-up. Moreover, 62 subjects with no benign liver disease were recruited as a control group in the same period. The serum level of HIF-1α and CRP were tested in case group and control group 1-week after TACE. The serum level of HIF-1α and CRP were compared among the recurrence, nonrecurrence, and benign liver disease patients. The predictive value of recurrence for serum HIF-1α, CRP was calculated by Bayes' theorem.
The serum HIF-1α and CRP level was arrayed 1-week after TACE. For recurrence cases, the serum level of HIF-1α and CRP was 2457.00 ± 335.70 pg/ml and 11.46 ± 3.25 mg/L. For nonrecurrence subjects, the serum level of HIF-1α and CRP was 2067.00 ± 175.900 pg/ml and 8.99 ± 1.70 mg/L. Moreover, for the benign liver disease patients, the serum level of HIF-1α and CRP was 1897.00 ± 121.33 pg/ml and 6.11 ± 1.2 mg/L. The serum level of HIF-1α and CRP was significantly higher in hepatocellular carcinoma patients than that of benign liver disease patients (P < 0.05); The recurrence predictive sensitivity and specificity of HIF-1α for hepatocellular carcinoma patients after TACE chemoembolization was 76.60% and 81.82% with the area under the curve (AUC) receiver operating characteristic (ROC) curve of 0.85; The recurrence predictive sensitivity and specificity of CRP for hepatocellular carcinoma patients after TACE was 65.96% and 63.64% with the AUC/ROC of 0.74.
The serum level of HIF-1α and CRP was elevated in recurrence patients which could be a potential marker for recurrence prediction.
本研究旨在评估经动脉化疗栓塞术（TACE）后肝细胞癌患者血清缺氧诱导因子-1α（HIF-1α）、C反应蛋白（CRP）对复发的预测价值。
选取2010年2月至2013年1月期间接受TACE治疗的58例肝细胞癌患者作为病例组。纳入的58例患者中，47例患者出现复发，其余11例在2年随访期内未复发。此外，同期招募62例无肝脏良性疾病的受试者作为对照组。在TACE术后1周检测病例组和对照组的血清HIF-1α和CRP水平。比较复发患者、未复发患者和肝脏良性疾病患者的血清HIF-1α和CRP水平。采用贝叶斯定理计算血清HIF-1α、CRP对复发的预测价值。
TACE术后1周测定血清HIF-1α和CRP水平。复发患者血清HIF-1α和CRP水平分别为2457.00±335.70 pg/ml和11.46±3.25 mg/L。未复发患者血清HIF-1α和CRP水平分别为2067.00±175.900 pg/ml和8.99±1.70 mg/L。此外，肝脏良性疾病患者血清HIF-1α和CRP水平分别为1897.00±121.33 pg/ml和6.11±1.2 mg/L。肝细胞癌患者血清HIF-1α和CRP水平显著高于肝脏良性疾病患者（P<0.05）；TACE化疗栓塞术后HIF-1α对肝细胞癌患者复发的预测敏感性和特异性分别为76.60%和81.82%，曲线下面积（AUC）的受试者工作特征（ROC）曲线为0.85；TACE术后CRP对肝细胞癌患者复发的预测敏感性和特异性分别为65.96%和63.64%，AUC/ROC为0.74。
复发患者血清HIF-1α和CRP水平升高，可能是复发预测的潜在标志物。
